CoLucid Pharmaceuticals Company Profile (NASDAQ:CLCD)

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals logoCoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLCD
  • CUSIP:
Key Metrics:
  • Previous Close: $39.65
  • 50 Day Moving Average: $34.67
  • 200 Day Moving Average: $20.14
  • 52-Week Range: $4.57 - $40.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.98
  • P/E Growth: 0.00
  • Market Cap: $764.07M
  • Outstanding Shares: 19,246,000
  • Beta: 1.57
Profitability:
  • Return on Equity: -81.71%
  • Return on Assets: -72.06%
Debt:
  • Current Ratio: 11.31%
  • Quick Ratio: 11.30%
Additional Links:
Companies Related to CoLucid Pharmaceuticals:

Analyst Ratings

Consensus Ratings for CoLucid Pharmaceuticals (NASDAQ:CLCD) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $48.67 (22.59% upside)

Analysts' Ratings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Show:
DateFirmActionRatingPrice TargetDetails
10/24/2016Stifel NicolausBoost Price TargetBuy$30.00 -> $40.00View Rating Details
9/30/2016Piper Jaffray Cos.Set Price TargetOverweight$36.00 -> $49.00View Rating Details
9/19/2016Ladenburg ThalmannSet Price TargetBuy$57.00View Rating Details
11/10/2015William BlairInitiated CoverageBuy$22.00View Rating Details
(Data available from 12/9/2014 forward)

Earnings

Earnings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
8/10/2016Q2($0.84)($1.06)ViewN/AView Earnings Details
5/11/2016Q1($0.73)($0.85)ViewN/AView Earnings Details
11/10/2015Q3($0.63)($0.59)ViewN/AView Earnings Details
8/12/2015($0.35)($1.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Current Year EPS Consensus Estimate: $-3.64 EPS
Next Year EPS Consensus Estimate: $-2.65 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.92)($0.92)($0.92)
Q4 20161($0.85)($0.85)($0.85)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 64.55%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/5/2016Linda C HoganInsiderSell2,583$37.77$97,559.91View SEC Filing  
12/5/2016Thomas P. MathersCEOSell1,502$38.75$58,202.50View SEC Filing  
12/1/2016Bernice KucaInsiderSell772$35.22$27,189.84View SEC Filing  
12/1/2016Matthew D. DallasCFOSell1,473$35.17$51,805.41View SEC Filing  
11/7/2016Linda C HoganInsiderSell1,862$28.56$53,178.72View SEC Filing  
11/7/2016Thomas P MathersCEOSell1,502$28.57$42,912.14View SEC Filing  
11/1/2016Linda C HoganInsiderSell719$30.00$21,570.00View SEC Filing  
10/5/2016Linda C HoganInsiderSell2,581$37.22$96,064.82View SEC Filing  
10/5/2016Thomas P MathersCEOSell1,502$37.08$55,694.16View SEC Filing  
9/14/2016Thomas P MathersCEOSell6,000$23.32$139,920.00View SEC Filing  
9/9/2016A/S NovoMajor ShareholderBuy100,000$20.00$2,000,000.00View SEC Filing  
9/7/2016Thomas P MathersCEOSell6,502$21.72$141,223.44View SEC Filing  
9/6/2016Linda C HoganInsiderSell48,736$19.87$968,384.32View SEC Filing  
8/31/2016Raymond SkwierczynskiInsiderSell150$10.86$1,629.00View SEC Filing  
8/19/2016Raymond SkwierczynskiInsiderSell508$8.41$4,272.28View SEC Filing  
8/10/2016Raymond SkwierczynskiInsiderSell508$8.30$4,216.40View SEC Filing  
8/5/2016Thomas P MathersCEOSell1,502$8.31$12,481.62View SEC Filing  
8/3/2016Domain Partners Vi, L.P.Major ShareholderSell153,028$8.45$1,293,086.60View SEC Filing  
7/29/2016Raymond SkwierczynskiInsiderSell508$9.09$4,617.72View SEC Filing  
7/20/2016Raymond SkwierczynskiInsiderSell508$8.97$4,556.76View SEC Filing  
7/11/2016Raymond SkwierczynskiInsiderSell508$9.10$4,622.80View SEC Filing  
6/30/2016Raymond SkwierczynskiInsiderSell516$7.01$3,617.16View SEC Filing  
6/20/2016Raymond SkwierczynskiInsiderSell1,008$6.80$6,854.40View SEC Filing  
6/6/2016Thomas P MathersCEOSell1,502$7.25$10,889.50View SEC Filing  
4/28/2016Vi Associates L.P. DpMajor ShareholderSell235$6.96$1,635.60View SEC Filing  
8/25/2015Thomas P MathersCEOBuy7,500$7.10$53,250.00View SEC Filing  
5/11/2015A/S NovoMajor ShareholderBuy1,300,000$10.00$13,000,000.00View SEC Filing  
5/11/2015Arthur M PappasDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CoLucid Pharmaceuticals (NASDAQ:CLCD)
DateHeadline
News IconChart Indicators in Focus for Colucid Pharmaceuticals Inc. (CLCD) - StockTalk Daily (NASDAQ:CLCD)
stocktalkdaily.com - December 8 at 6:26 AM
News IconFollowing FCF Scores for CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - The Business Journal (NASDAQ:CLCD)
belmontbusinessjournal.com - December 7 at 7:13 AM
investing.com logo4 Stocks To Watch: CLCD, EXEL, KEM, NDRM (NASDAQ:CLCD)
www.investing.com - December 6 at 11:55 AM
fool.com logo3 Small-Cap Biotech Stocks That Could Double in 2017 (NASDAQ:CLCD)
www.fool.com - December 2 at 4:41 PM
investornewswire.com logoBuy Calls Of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) At 0 - Investor Newswire (NASDAQ:CLCD)
www.investornewswire.com - December 1 at 9:27 PM
News IconFree Cash Flow Score in Focus for CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - The Business Journal (NASDAQ:CLCD)
belmontbusinessjournal.com - November 30 at 9:28 PM
finance.yahoo.com logoCoLucid Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference (NASDAQ:CLCD)
finance.yahoo.com - November 30 at 8:31 AM
News IconInvestors are Watching Shares of CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - The Business Journal (NASDAQ:CLCD)
belmontbusinessjournal.com - November 22 at 3:48 PM
nasdaq.com logoCoLucid (CLCD): Strong Industry, Solid Earnings Estimate ... - Nasdaq - Nasdaq (NASDAQ:CLCD)
www.nasdaq.com - November 22 at 3:48 PM
finance.yahoo.com logoCoLucid (CLCD): Strong Industry, Solid Earnings Estimate Revisions (NASDAQ:CLCD)
finance.yahoo.com - November 22 at 3:48 PM
News IconCoLucid Pharmaceuticals, Inc. CLCD Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:CLCD)
www.bioportfolio.com - November 21 at 4:32 PM
News IconTrading Watch: FCF and Piotroski Score Check for CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Wall Street Lion (NASDAQ:CLCD)
wslnews.com - November 21 at 9:12 AM
News IconInvestor Focus on Technical Levels for Colucid Pharmaceuticals Inc. (CLCD) - StockTalk Daily (NASDAQ:CLCD)
stocktalkdaily.com - November 21 at 9:12 AM
News IconStock Watch: Focusing in on CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Marion Business Daily (NASDAQ:CLCD)
marionbusinessdaily.com - November 18 at 8:35 PM
News IconCoLucid Pharmaceuticals, Inc.'s (CLCD): Shares in the Trader's Spot light - Hot Stocks Point (NASDAQ:CLCD)
www.hotstockspoint.com - November 18 at 8:35 PM
finance.yahoo.com logoCOLUCID PHARMACEUTICALS, INC. Financials (NASDAQ:CLCD)
finance.yahoo.com - November 17 at 3:29 PM
News IconTechnical Buzz on CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Wall Street Lion (NASDAQ:CLCD)
wslnews.com - November 17 at 11:06 AM
News IconChecking the Levels on Shares of CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - Marion Business Daily (NASDAQ:CLCD)
marionbusinessdaily.com - November 16 at 9:31 AM
News IconCoLucid Pharmaceuticals, Inc. CLCD Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CLCD)
www.bioportfolio.com - November 15 at 10:33 PM
globenewswire.com logoCoLucid Pharmaceuticals Provides SPARTAN Enrollment Update ... - GlobeNewswire (press release) (NASDAQ:CLCD)
globenewswire.com - November 15 at 4:34 PM
marketwatch.com logoStock market speculation is alive and well, suggesting higher prices ahead (NASDAQ:CLCD)
www.marketwatch.com - November 15 at 9:38 AM
publicnow.com logoCoLucid Pharmaceuticals Provides SPARTAN Enrollment Update (NASDAQ:CLCD)
www.publicnow.com - November 14 at 4:25 PM
News IconUpgrades And Downgrades For CoLucid Pharmaceuticals, Inc ... - NewsDen (NASDAQ:CLCD)
newsden.net - November 12 at 11:30 AM
News IconStock Tracker: Earnings & Estimates for CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - CSZ News (NASDAQ:CLCD)
cincysportszone.com - November 10 at 11:02 AM
marketexclusive.com logoCoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) Files An 8-K Announces 2016 Third Quarter Results and Corporate Highlights (NASDAQ:CLCD)
marketexclusive.com - November 9 at 4:24 PM
biz.yahoo.com logoCOLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:CLCD)
biz.yahoo.com - November 9 at 11:57 AM
biz.yahoo.com logoCOLUCID PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CLCD)
biz.yahoo.com - November 9 at 11:57 AM
finance.yahoo.com logo8:05 am CoLucid Pharmaceuticals reports Q3 results, provides corporate update (NASDAQ:CLCD)
finance.yahoo.com - November 9 at 11:57 AM
publicnow.com logoCoLucid Pharmaceuticals Announces 2016 Third Quarter Results and Corporate Highlights (NASDAQ:CLCD)
www.publicnow.com - November 9 at 11:57 AM
finance.yahoo.com logoCoLucid Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference (NASDAQ:CLCD)
finance.yahoo.com - November 8 at 1:45 PM
investornewswire.com logoCan Shares Of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Hit $52? - Investor Newswire (NASDAQ:CLCD)
www.investornewswire.com - November 5 at 11:46 AM
News IconEarnings Take Center Stage; Analysts Weighing in on CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - CSZ News (NASDAQ:CLCD)
cincysportszone.com - November 2 at 10:29 PM
News IconGaining on an Upswing are Shares of CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) - CSZ News (NASDAQ:CLCD)
cincysportszone.com - November 2 at 9:45 AM
News IconWhy After A Massive Run, CoLucid Shares Still Look Attractive (NASDAQ:CLCD)
www.bionapcfa.com - November 1 at 4:22 PM
News IconStock Clipped Lower in Past Week: CoLucid Pharmaceuticals, Inc ... - CSZ News (NASDAQ:CLCD)
cincysportszone.com - October 30 at 4:15 PM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Spectrum Pharma, Pain Therapeutics, CoLucid Pharma, and CEL-SCI - PR Newswire (press release) (NASDAQ:CLCD)
www.prnewswire.com - October 28 at 3:59 PM
4-traders.com logoCEL SCI : Research Reports Initiation on Biotech Stocks -- Spectrum Pharma, Pain Therapeutics, CoLucid Pharma, and CEL-SCI (NASDAQ:CLCD)
www.4-traders.com - October 28 at 8:26 AM
marketwatch.com logoResearch Reports Initiation on Biotech Stocks -- Spectrum Pharma, Pain Therapeutics, CoLucid Pharma, and CEL-SCI (NASDAQ:CLCD)
www.marketwatch.com - October 28 at 8:26 AM
investornewswire.com logoCoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Buy Calls At 0 - Investor Newswire (NASDAQ:CLCD)
www.investornewswire.com - October 27 at 9:48 PM
streetinsider.com logoCoLucid Pharmaceuticals (CLCD) PT Raised to $40 at Stifel Following NDR - StreetInsider.com (NASDAQ:CLCD)
www.streetinsider.com - October 24 at 4:09 PM
News IconSell-side Taking Aim at Shares of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) - CSZ News (NASDAQ:CLCD)
cincysportszone.com - October 19 at 4:05 PM

Social

CoLucid Pharmaceuticals (NASDAQ:CLCD) Chart for Friday, December, 9, 2016


Last Updated on 12/9/2016 by MarketBeat.com Staff